Benzinga · Sep 30, 2026
CalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock Offering
https://www.sec.gov/Archives/edgar/data/1534133/000119312526409041/d145394d424b5.htm
CA
NASDAQ · CALC
CalciMedica, Inc.
Healthcare · Biotechnology
$1.54
Down-$0.05 (-3.25%)
Updated Oct 6, 2026, 9:41 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 66.14M
- P/E ratio
- -3,000.91
- Dividend yield
- 0.00%
- 52-week range
- $0.46 – $7.20
- Volume
- 26.63K
- Avg. volume
- 67.77K
Price performance · CALC
CALC price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CALC closed at $1.54 after 20 trading sessions, down 23.76% for the selected period.
- Last close
- $1.54
- Period change
- -23.76%
- Period low
- $1.54
- Period high
- $2.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.625 | $1.625 | $1.53 | $1.54 | 26.63K |
| Oct 2, 2026 | $1.64 | $1.70 | $1.58 | $1.60 | 21.83K |
| Oct 1, 2026 | $1.62 | $1.7094 | $1.60 | $1.65 | 25.93K |
| Sep 30, 2026 | $1.67 | $1.67 | $1.60 | $1.62 | 38.66K |
| Sep 29, 2026 | $1.70 | $1.70 | $1.58 | $1.61 | 43.12K |
| Sep 28, 2026 | $1.75 | $1.75 | $1.62 | $1.68 | 26.59K |
| Sep 25, 2026 | $1.73 | $1.765 | $1.62 | $1.75 | 41.43K |
| Sep 24, 2026 | $1.81 | $1.81 | $1.71 | $1.74 | 54.53K |
| Sep 23, 2026 | $1.87 | $1.885 | $1.76 | $1.79 | 70.14K |
| Sep 22, 2026 | $1.93 | $1.9793 | $1.76 | $1.87 | 97.01K |
| Sep 21, 2026 | $1.95 | $1.9551 | $1.86 | $1.86 | 50.44K |
| Sep 18, 2026 | $1.98 | $1.9983 | $1.92 | $1.92 | 60.24K |
| Sep 17, 2026 | $1.97 | $2.035 | $1.92 | $1.97 | 98.73K |
| Sep 16, 2026 | $1.995 | $2.06 | $1.94 | $1.98 | 68.54K |
| Sep 15, 2026 | $2.00 | $2.0416 | $1.94 | $1.98 | 55.06K |
| Sep 14, 2026 | $1.97 | $2.02 | $1.87 | $2.00 | 101.28K |
| Sep 11, 2026 | $2.085 | $2.15 | $1.96 | $1.98 | 23.15K |
| Sep 10, 2026 | $2.22 | $2.29 | $2.07 | $2.12 | 83.31K |
| Sep 9, 2026 | $2.03 | $2.31 | $1.91 | $2.295 | 185.62K |
| Sep 8, 2026 | $2.11 | $2.15 | $1.9915 | $2.02 | 122.61K |
Latest CALC news
The latest Smart Investors Daily articles mentioning CALC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CALC research
Overview
Company profile and research snapshot.
Company profile
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $266.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Guggenheim | Buy | — |
| Mar 5, 2026 | Oppenheimer | Outperform | — |
| Jan 29, 2026 | HC Wainwright & Co. | Neutral | — |
| May 15, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 16, 2026
CalciMedica Regains Nasdaq Compliance
-SEC Filing
Yahoo · Sep 8, 2026
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.
Yahoo · Aug 27, 2026
CalciMedica Announces One-for-Five Reverse Stock Split
CalciMedica’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 31, 2026LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that it will effect a reverse stock split of its issued and outstanding co
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
